TIME convened the first-ever TIME100 Health Leadership Forum to bring together individuals driving innovation and creating equitable initiatives within the health sector.

Zacks Research lowered their Q3 2024 earnings estimates for Merck & Co., Inc. in a report issued on Monday, October 21st.

In recent trading, Merck & Co Inc (MRK) stock price has shown some volatility, fluctuating -3.05% over the last five trades and -9.24% over the past 30 trades. This represents a notable shift from ...

Empowering young women with the confidence to excel in their education is key to inspiring the next generation' ...

Pembrolizumab plus chemotherapy improves disease-free survival (DFS) in patients with high-risk endometrial cancer aft ...

Global Clostridium Difficile Infections Treatment MarketThe global Clostridium Difficile Infections (CDI) treatment market is ...

Standigm uses Synthia Retrosynthesis Software from Merck KGaA, Darmstadt, Germany, to accelerate its drug design and synthesis processes driving advancements in pharmaceutical development. Standigm ...

Global donor egg IVF (in-vitro fertilization) market is estimated to be valued at USD 2.85 Bn in 2024 and is expected to reach USD 5.30 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9 ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

The global vaginitis treatment drug market is experiencing robust growth, with projections indicating a remarkable increase ...

SEATTLE, Oct. 04, 2024 (GLOBE NEWSWIRE) -- (OTC Pink: KANT) , a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune ...